SG/CALL/EDWARDS LIFESCIENCES/75/0.1/20.12.24 | Delayed Deutsche Boerse AG 06:01:40 2024-07-12 am EDT | ||
| 1.99 EUR | -3.40% |
|
| Current month | +0.49% | ||
| 1 month | +18.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about EDWARDS LIFESCIENCES CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 1.99 | -3.40% |
| 24-07-11 | 2.06 | -1.90% |
| 24-07-10 | 2.1 | +0.48% |
| 24-07-09 | 2.09 | +6.63% |
| 24-07-08 | 1.96 | -1.51% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 06:01 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | EDWARDS LIFESCIENCES CORPORATION |
| Issuer | 
Société Générale
|
| WKN | SU2MAN |
| ISIN | DE000SU2MAN7 |
| Date issued | 2023-11-22 |
| Strike | 75 $ |
| Maturity | 2024-12-20 (162 Days) |
| Parity | 10 : 1 |
| Emission price | 1.12 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.73 € |
|---|---|
| Lowest since issue | 1.02 € |
| Spread | 0.09 € |
| Spread % | 4.31% |
Company Profile
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Sector
-
Ratings for Edwards Lifesciences Corporation
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Edwards Lifesciences Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
92.85
USD
Average target price
96.16
USD
Spread / Average Target
+3.57%
- Stock Market
- Warrants
- Warrant